Mucosal Immunity

Mucosal Immunity describes immune defence mechanisms operating at mucosal surfaces including the gastrointestinal tract, respiratory tract, and urogenital system, which collectively represent major entry points for pathogens. These specialised immune environments balance protection against infectious agents with tolerance to harmless antigens. Key components include secretory IgA antibodies, mucosal-associated lymphoid tissues, epithelial barrier integrity, innate immune cells, and local cytokine networks.

The biopharmaceutical industry increasingly focuses on mucosal immunity in vaccine development, infectious disease prevention, and immune-mediated disease management. Mucosal vaccines aim to induce local protective responses, particularly secretory IgA and tissue-resident memory cells, offering advantages for respiratory viruses and enteric pathogens by blocking infection at the point of entry. Intranasal and oral vaccine platforms are actively explored for improved accessibility and broader immune protection, though formulation stability and delivery challenges remain. Mucosal immunity also plays critical roles in inflammatory bowel disease, asthma, and food allergy, driving therapeutic strategies targeting barrier function, immune regulation, and microbiota interactions. As understanding deepens regarding mucosal immune architecture and microbiome interplay, mucosal immunity becomes increasingly central to designing next-generation vaccines and immunomodulatory therapies.